The DTWD2 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal human cell population in the A2780 ovarian carcinoma background, providing a pooled loss-of-function model for the uncharacterized gene DTWD2. This product consists of a heterogeneous pool of cells harboring diverse Cas9-mediated edits at the DTWD2 locus, enabling robust functional genomics studies without requiring single-cell cloning. The polyclonal format preserves genetic diversity and mitigates clonal artifacts, making it suitable for downstream assays that demand representative population-level responses.
The A2780 cell line is an epithelial ovarian cancer model established from an untreated patient with ovarian endometrioid adenocarcinoma. These cells recapitulate key features of high-grade serous ovarian carcinoma and are widely employed in cancer biology to study tumor cell proliferation, apoptosis, drug resistance, and epithelial-mesenchymal transition. Their well-characterized growth kinetics and sensitivity to platinum-based chemotherapeutics make A2780 an ideal host for CRISPR-based gene disruption experiments aimed at dissecting molecular determinants of ovarian cancer behavior.
DTWD2 encodes a DTW domain-containing protein of unknown molecular function. The DTW domain, named after the conserved DTW motif, is found in proteins across eukaryotes and is structurally related to enzymes involved in nucleotide metabolism and RNA processing. Bioinformatics analyses predict that DTWD2 may participate in nucleic acid binding, modification, or cellular regulatory pathways, although its specific substrates, interacting partners, and upstream regulators remain unidentified. Thus, the DTWD2 knockout in A2780 cells serves as a discovery tool to probe these fundamental biological questions and to define its role within the cellular signaling milieu.
In the context of ovarian cancer, the DTWD2 knockout model offers a unique opportunity to investigate the gene??s contribution to malignant phenotypes. By comparing the polyclonal knockout population to wild-type A2780 cells, researchers can identify changes in cell viability, colony-forming ability, apoptotic susceptibility, and drug response profiles. This may reveal whether DTWD2 acts as a permissive or restrictive factor in ovarian cancer progression and could uncover synthetic lethal interactions or sensitization to existing therapeutics. Such insights are critical for prioritizing DTWD2 as a potential biomarker or therapeutic target in ovarian carcinoma.
This product is designed for a variety of advanced research applications, including functional genomics, CRISPR screen validation, and mechanistic studies of ovarian cancer. Representative assays include RT-qPCR and Western blotting to confirm gene disruption, immunofluorescence to assess protein localization, and phenotypic assays such as proliferation, colony formation, apoptosis, and drug sensitivity testing. The polyclonal nature ensures that observed effects are representative of the edited population. For technical assistance or customized solutions, please contact Ascent Research.
